CAMP4 reports Q2 net loss of $12.6M; cash $39.1M; pipeline advances in SYNGAP1 and UCD programs

Camp4 Therapeutics Corp

2025-Q2 EPS reported -$1.24 vs consensus -$0.69 ▼ miss (-80.9%)

Net loss of $12.6M for Q2 2025, flat vs Q2 2024; R&D expenses $10.3M, G&A $4.2M.
Cash, cash equivalents and marketable securities $39.1M as of June 30, 2025, down from $49.3M on March 31, 2025.
SYNGAP1 program: translational data presented at ASGCT; GLP tox studies start Q3 2025; potential Phase 1/2 trial in H2 2026.
CMP-CPS-001 (UCD): completed dosing in MAD cohort 3; safety and biomarker data from SAD and MAD cohorts expected Q4 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.